amgen glp 1 drug Amgen's obesity may help patients keep the weight off The Gap Between GLP-1 Prescriptions

Description

Read here for more information on the class of drugs known as GLP-1 agonists

Several macro and micro-level drivers are driving this obesity care revolution: Rising Prevalence : By 2030, nearly half the worlds population will be living with overweight or obesity, an alarming epidemiological trend that brings public health systems to a tipping point

While most major insurers and Medicare plans cover GLP-1s for T2D, coverage for GLP-1s for obesity and weight management is much more limited and often excluded from standard plans

Stimulation of GLP-1R via G protein -subunits increases adenylate cyclase activity, leading to increased adenosine triphosphate (ATP) production and elevated cyclic adenosine monophosphate (cAMP) levels, which in turn activate secondary pathways, including protein kinase A (PKA), phosphoinositide 3-kinase (PI3K), and mitogen-activated protein kinase (MAPK) signaling pathways [16]